|
|
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma
Guillemette Fouquet
,
Lionel Karlin
,
Margaret Macro
,
Denis Caillot
,
Murielle Roussel
et al.
Journal articles
hal-01728968v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Salvage Therapy Post Pomalidomide-Based Regimen in Relapsed/Refractory Myeloma
Guillemette Fouquet
,
Lionel Karlin
,
Margaret Macro
,
Denis Caillot
,
Murielle Roussel
et al.
Blood, 2015, 126 (23), pp.1831
Journal articles
hal-01300804v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
Maroulio Pertesi
,
Maxime Vallée
,
Xiaomu Wei
,
Maria Revuelta
,
Perrine Galia
et al.
Journal articles
hal-02190723v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Xavier Leleu
,
Lionel Karlin
,
Margaret Macro
,
Cyrille Hulin
,
Laurent Garderet
et al.
Journal articles
hal-01141134v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
Arthur Bobin
,
Maéva Kyheng
,
Stephanie Guidez
,
Cecile Gruchet-Merouze
,
Valentine Richez
et al.
Journal articles
hal-03476700v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs
Xavier Leleu
,
Philippe Rodon
,
Cyrille Hulin
,
Laurent Daley
,
Charles Dauriac
et al.
Journal articles
hal-01064326v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL
Xavier Leleu
,
Lionel Karlin
,
Brigitte Kolb
,
Mourad Tiab
,
Carla Araujo
et al.
Blood, 2015, 126 (23), pp.3028
Journal articles
hal-01290431v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
Xavier Leleu
,
Michel Attal
,
Bertrand Arnulf
,
Philippe Moreau
,
Catherine Traulle
et al.
Journal articles
hal-01064417v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|